Navigation Links
BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease
Date:8/30/2010

NOVATO, Calif., Aug. 30 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for BMN-701, a novel fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for the treatment of Pompe disease.  An investigational new drug application (IND) for BMN-701 has been submitted, investigational material has been manufactured and a Phase I/II study is expected to start in the first quarter of 2011.

"Receiving orphan drug designation from the FDA for BMN-701 is a significant milestone for our Pompe program.  As part of their assessment for designation, the FDA determined that BMN-701 is sufficiently different from alglusidase alfa (Myozyme/Lumizyme) to allow for a unique orphan designation.  For this reason, clinical superiority over alglusidase alfa will not be necessary to secure orphan exclusivity for BMN-701," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin.  "This emphasizes our mission of developing innovative, products for orphan diseases with an unmet medical need.  We believe BMN-701 has the potential to possibly deliver more enzyme to lysosomes compared to traditional mannose-6-phosphate targeted approaches using the recently acquired GILT technology."  

About Pompe DiseasePompe disease, a lysosomal storage disorder, is a progressive degenerative disease of the heart muscle, diaphragm and skeletal muscle.  It is caused by a deficiency in the lysosomal enzyme acid alpha glucosidase which leads to the accumulation of glycogen in myocyte lysosomes and results in cell death.  The incidence is one in 40,000 births.  There are two main forms of Pompe disease: adult onset with an incidence of one in 57,000 births and infantile onset with an incidence of one in
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. BioMarin Announces FDA Approval for Kuvan
3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
8. BioMarin to Present at the Oppenheimer Healthcare Conference
9. BioMarin Announces Third Quarter 2009 Financial Results
10. BioMarin to Acquire LEAD Therapeutics
11. BioMarin to Present at the Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... and sale of patented biopharmaceutical medicine, modernized traditional Chinese ... today announced the business and development progress at its ... Following the September 2014 JCM application (No. 51268) for ...
(Date:1/22/2015)... Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty ... disease and overall health is pleased to provide you with ... outlook for 2015 from the CEO, Mr. Eugene Bortoluzzi ... like to take this opportunity to share with you the ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/3h534b/infectious ) has announced ... by Product, Application, Technology, End User - Global Forecast ... The infectious disease diagnostics market is expected to ... by 2019 from $12,422.8 million in 2014. Increase in ...
Breaking Medicine Technology:TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3
... , GREENWOOD VILLAGE, Colo. , June 28 ... cycle solutions for the healthcare industry, announced today the ... to integrate various and disparate hospital systems, applications, software ... were designed and developed decades ago, hospitals have been ...
... that a new market research report is available in its catalogue: , ... Global Acute Coronary Syndrome industry , ... http://www.reportlinker.com/p0197235/Global-Acute-Coronary-Syndrome-industry.html , , , ... for Acute Coronary Syndrome Therapeutics in US$ Million. Annual estimates and forecasts are provided for ...
Cached Medicine Technology:Recondo Technology Announces Integration Initiative for US Hospital Systems 2Recondo Technology Announces Integration Initiative for US Hospital Systems 3Recondo Technology Announces Integration Initiative for US Hospital Systems 4Global Acute Coronary Syndrome Industry 2Global Acute Coronary Syndrome Industry 3Global Acute Coronary Syndrome Industry 4Global Acute Coronary Syndrome Industry 5Global Acute Coronary Syndrome Industry 6Global Acute Coronary Syndrome Industry 7Global Acute Coronary Syndrome Industry 8Global Acute Coronary Syndrome Industry 9Global Acute Coronary Syndrome Industry 10Global Acute Coronary Syndrome Industry 11Global Acute Coronary Syndrome Industry 12Global Acute Coronary Syndrome Industry 13Global Acute Coronary Syndrome Industry 14Global Acute Coronary Syndrome Industry 15Global Acute Coronary Syndrome Industry 16Global Acute Coronary Syndrome Industry 17Global Acute Coronary Syndrome Industry 18
(Date:1/22/2015)... California (PRWEB) January 22, 2015 The City of ... at 10 a.m., to commemorate the 42nd anniversary of the Supreme ... States. , “It’s been 42 years since the Roe vs. Wade ... is still as present as ever,” said City of West Hollywood ...
(Date:1/22/2015)... January 22, 2015 The Incredible Bulk is ... Pakulski to increase lean muscle by up to 30lbs in ... the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. ... is a step-by-step, scientific diet formula that allows the body ...
(Date:1/22/2015)... 22, 2015 Juvent Sports ( http://www.juventsports.com ... 2015 PGA Merchandise Show to bestow a Juvent Sports ... amateur golfer, Arlene McKitrick. The award commemorated and congratulated ... tournament win. She won her first amateur tournament in ...
(Date:1/22/2015)... 2015 Carinsurancesavings.biz has released a new blog ... dismemberment insurance . , Purchasing an accidental death and ... advantageous. This type of rider provides benefits if the insured ... considered a lesser form of life insurance. , AD&D ...
(Date:1/22/2015)... 22, 2015 IsoComforter, Inc. has introduced the ... patented IsoTube design to treat specific body parts and muscle ... progressive and easy to use patented cold therapy machine with ... related orthopedic and muscle injuries. IsoComforter has become the ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... of the,nation,s largest providers of emergency department (ED) management ... in Berwyn,Ill., to run its ED starting Jan. 1, ... in 1975 by ED physicians driven to improve the ... CEP America focuses solely on,developing ED solutions for hospitals ...
... ASHP Midyear Clinical,Meeting and Exhibition -- Omnicell, ... provider of,system solutions to acute healthcare facilities, and ... Harvard Medical School located in,the heart ... the,planned installation of Omnicell,s SinglePointe(TM) automated patient-specific,medication management ...
... food costs, many,families are economizing on groceries but one ... about 25 cents per 8-ounce glass, on a gallon ... other beverage option in the,supermarket -- providing key vitamins ... for the entire family. To ensure moms don,t cut ...
... that Dr. Jonathan White will join the Company as head ... 8, 2008. In this role, Dr. White will have ... products to complement Haemonetics, blood management solutions portfolio. , ... CEO, said, "As the global leader in blood management solutions ...
... Maine, Dec. 8 IDEXX Laboratories, Inc. (Nasdaq: ... E. Brown, PhD as Corporate Vice President, Instrument Research ... Brown will oversee instrument development, manufacturing, and the worldwide ... "Bill,s extensive R&D and manufacturing management experience is distinctively ...
... Inc. (Nasdaq: HGSI ) today announced that it will sponsor ... 3 trial of Albuferon(R) (albinterferon alfa-2b) in chronic hepatitis C. , ... , The conference call will be hosted by ... 8:15 am Eastern Time. , , Investors ...
Cached Medicine News:Health News:CEP America Partners With MacNeal Hospital to Provide Emergency Department Management, Staffing 2Health News:Brigham and Women's Hospital Selects SinglePointe(TM) Automated Patient-Specific Medication Management Solution from Omnicell 2Health News:Brigham and Women's Hospital Selects SinglePointe(TM) Automated Patient-Specific Medication Management Solution from Omnicell 3Health News:Milk is One Beverage Jackson Can't Afford to Keep Off the Grocery List 2Health News:Milk is One Beverage Jackson Can't Afford to Keep Off the Grocery List 3Health News:Dr. Jonathan White Joins Haemonetics as Head of Research and Development 2Health News:IDEXX Laboratories Names William Brown Corporate Vice President 2Health News:Human Genome Sciences to Sponsor Conference Call 2
The Adjustable Large Fixator is a one-piece fixator with a radiolucent body. It has a multifunctional design pivoting pin clamp for use in ankle or tibial plateau fractures....
Provides basic reduction capabilities for angulation, rotation and length. Ball joint design offers fracture reduction in all planes....
... the Pennig Minifixator, combines the advantage of secure ... tissue dissection is not necessary, since in general, ... fixation in the hand has required bridging of ... (Asche and Burny) because of the design of ...
... The two principal goals of the DJD® II ... the elbow and to protect the articular surfaces ... allowed by a hinge which is designed to ... integrated distraction mechanism prevents the articular surfaces from ...
Medicine Products: